Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AMG 557 in SLE
NCT02391259Phase 1Completed
- Sponsor
- Amgen
- Start
- Nov 2006
- Primary completion
- Sep 2011
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing AMG 557 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Nov 2006; status: completed.
02
Drugs
prezalumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02391259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02391259.